Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/oncology clinics of North America Narayanan, S., Kunz, P. L. 2016; 30 (1): 163-177


Neuroendocrine tumors (NETs) are rare epithelial neoplasms with neuroendocrine differentiation originating most commonly in the lungs and gastroenteropancreatic. Treatment includes surgery and other local therapies; treatment of inoperable disease centers around symptom management and control of tumor growth. Somatostatin analogues (SSAs) have been a mainstay of managing hormone-related symptoms. Emerging evidence suggests that they are effective therapies for tumor control also. Peptide receptor radionuclide therapy with radiolabeled SSAs is a new, promising treatment for inoperable or metastatic NETs. This article reviews the role of SSAs in the treatment of NETs.

View details for DOI 10.1016/j.hoc.2015.09.008

View details for PubMedID 26614375